

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market - 2025-2033

<https://marketpublishers.com/r/GB93C7AE8C4AEN.html>

Date: April 2026

Pages: 186

Price: US\$ 2,999.00 (Single User License)

ID: GB93C7AE8C4AEN

Abstracts

The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market was valued at US\$ 8.56 Billion in 2025 and is anticipated to reach US\$ 31.76 Billion by 2033, at a CAGR of 0.177 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market.

This report delivers a comprehensive overview of the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market. The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market Scope:

By Drug Class

Thyroid Hormone Receptor- α (THR- α) Agonists

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists

GLP-1 Receptor Agonists

GLP-1 / Glucagon Dual Receptor Agonists

Fibroblast Growth Factor 21 (FGF21) Analogues

Acetyl-CoA Carboxylase (ACC) Inhibitors

Others

By Fibrosis Stage

F0–F1

F2–F3

F4

By Age Group

Adults

Geriatrics

Pediatrics

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By End User

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Key Players

Madrigal Pharmaceuticals, Inc.

Novo Nordisk A/S

Boehringer Ingelheim International GmbH

Akero Therapeutics, Inc.

89bio, Inc.

Inventiva

Sagimet Biosciences Inc.

Viking Therapeutics

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

Gilead Sciences, Inc. .

Major Highlights

This report delivers a comprehensive overview of the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market, with both quantitative and qualitative

analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market. The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Global Burden of Obesity and Metabolic Syndrome
 - 3.1.1.2. Advancements in Drug Development and Clinical Research
 - 3.1.1.3. Increasing Awareness and Diagnosis of Liver Diseases
 - 3.1.2. Restraints
 - 3.1.2.1. Lack of Widely Approved and Effective Therapies
 - 3.1.2.2. High Treatment Costs and Limited Reimbursement
 - 3.1.2.3. Stringent Regulatory Requirements for Drug Approval
 - 3.1.3. Opportunity
 - 3.1.3.1. Growing Demand for Effective Therapies for Untreated MASH Population
 - 3.1.3.2. Increasing Adoption of Precision Medicine and Targeted Therapies
 - 3.1.4. Trends
 - 3.1.4.1. Expansion of GLP-1-Based Therapeutic Approaches
 - 3.1.4.2. Rising Clinical Trials and Strong Drug Development Pipeline
 - 3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

- 4.1. Porter's Five Force Analysis – Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market
- 4.2. Geopolitical & Supply Chain Exposure
 - 4.2.1. API sourcing concentration for MASH drug development and manufacturing
 - 4.2.2. Trade policies, export controls, and pharmaceutical supply chain risks
- 4.3. Social & Patient-Centric Factors
 - 4.3.1. Physician prescribing behavior in metabolic and liver disease treatment
 - 4.3.2. Patient adherence challenges in long-term metabolic and liver disease therapies
 - 4.3.3. Treatment switching patterns between metabolic and liver disease therapies
 - 4.3.4. Awareness gaps and underdiagnosis of MASH among at-risk populations
- 4.4. Economic Factors
 - 4.4.1. Healthcare expenditure and reimbursement policies for MASH therapies
 - 4.4.2. Rising R&D costs and manufacturing expenses for innovative liver disease drugs
 - 4.4.3. Economic burden of metabolic disorders and impact on treatment demand
- 4.5. Pricing Analysis
 - 4.5.1. Pricing dynamics of innovative MASH therapies and emerging treatment options
- 4.6. Regulatory Analysis
 - 4.6.1. Regulatory approval pathways for MASH drug candidates
 - 4.6.2. Post-marketing surveillance and pharmacovigilance requirements
 - 4.6.3. GMP compliance and regulatory inspection risks in pharmaceutical manufacturing
 - 4.6.4. Regulatory alignment across major agencies, including FDA, EMA, PMDA, NMPA, and CDSCO
- 4.7. Go-To-Market (GTM) Strategy
 - 4.7.1. Hospital, specialty clinic, and hepatology network penetration strategies
- 4.8. Innovation & R&D Trends
 - 4.8.1. Development of next-generation metabolic and anti-fibrotic therapies
 - 4.8.2. Combination therapy strategies targeting metabolic dysfunction and liver fibrosis
- 4.9. Sustainability and ESG Analysis
 - 4.9.1. Responsible sourcing of pharmaceutical ingredients and sustainable manufacturing practices
- 4.10. Ecosystem Participants
 - 4.10.1. Branded MASH drug developers and pharmaceutical companies
 - 4.10.2. Biotechnology firms developing novel metabolic and liver disease therapies
 - 4.10.3. API and pharmaceutical ingredient suppliers

- 4.10.4. Contract research, manufacturing, and packaging organizations
- 4.10.5. Healthcare providers, distributors, and specialty pharmacy networks
- 4.11. Buyer Decision Criteria & Adoption Drivers
 - 4.11.1. Clinical efficacy and safety profile of emerging MASH therapies
 - 4.11.2. Regulatory approval status and clinical evidence
 - 4.11.3. Pricing, reimbursement, and patient access programs
 - 4.11.4. Treatment outcomes and long-term disease management benefits
- 4.12. DMI Opinion – Strategic Outlook for the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market

5. BY DRUG CLASS

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 5.1.2. Market Attractiveness Index, By Drug Class
- 5.2. Thyroid Hormone Receptor-? (THR-?) Agonists*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 5.2.3. Resmetirom
 - 5.2.4. VK2809
- 5.3. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
 - 5.3.1. Lanifibranor
- 5.4. GLP-1 Receptor Agonists
 - 5.4.1. Semaglutide
- 5.5. GLP-1 / Glucagon Dual Receptor Agonists
 - 5.5.1. Survodutide
- 5.6. Fibroblast Growth Factor 21 (FGF21) Analogues
 - 5.6.1. Pegozafermin
 - 5.6.2. Efruxifermin
- 5.7. Acetyl-CoA Carboxylase (ACC) Inhibitors
 - 5.7.1. Denifanstat
- 5.8. Others

6. BY FIBROSIS STAGE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
 - 6.1.2. Market Attractiveness Index, By Fibrosis Stage
- 6.2. F0–F1*

- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. F2–F3
- 6.4. F4

7. BY AGE GROUP

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 7.1.2. Market Attractiveness Index, By Age Group
- 7.2. Adults*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Geriatrics
- 7.4. Pediatrics

8. BY DISTRIBUTION CHANNEL

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail Pharmacies
- 8.4. Online Pharmacies

9. BY END USER

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 9.1.2. Market Attractiveness Index, By End User
- 9.2. Hospitals*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Specialty Clinics
- 9.4. Ambulatory Surgical Centers

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.8.1. US

10.2.8.2. Canada

10.2.8.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.8.1. Germany

10.3.8.2. United Kingdom

10.3.8.3. France

10.3.8.4. Italy

10.3.8.5. Spain

10.3.8.6. Netherlands

10.3.8.7. Switzerland

10.3.8.8. Sweden

10.3.8.9. Norway

10.3.8.10. Denmark

10.3.8.11. Belgium

10.3.8.12. Poland

10.3.8.13. Austria

10.3.8.14. Ireland

- 10.3.8.15. Portugal
- 10.3.8.16. Greece
- 10.3.8.17. Finland
- 10.3.8.18. Rest of Europe
- 10.4. Latin America
 - 10.4.1. Introduction
 - 10.4.2. Key Region-Specific Dynamics
 - 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
 - 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.4.8.1. Brazil
 - 10.4.8.2. Argentina
 - 10.4.8.3. Mexico
 - 10.4.8.4. Chile
 - 10.4.8.5. Colombia
 - 10.4.8.6. Peru
 - 10.4.8.7. Rest of Latin America
- 10.5. Asia-Pacific
 - 10.5.1. Introduction
 - 10.5.2. Key Region-Specific Dynamics
 - 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
 - 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.5.8.1. China
 - 10.5.8.2. Japan
 - 10.5.8.3. India
 - 10.5.8.4. South Korea
 - 10.5.8.5. Australia
 - 10.5.8.6. New Zealand
 - 10.5.8.7. Singapore
 - 10.5.8.8. Malaysia
 - 10.5.8.9. Thailand
 - 10.5.8.10. Indonesia

- 10.5.8.11. Vietnam
- 10.5.8.12. Philippines
- 10.5.8.13. Taiwan
- 10.5.8.14. Rest of Asia Pacific
- 10.6. Middle East and Africa
 - 10.6.1. Introduction
 - 10.6.2. Key Region-Specific Dynamics
 - 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
 - 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.6.8.1. Saudi Arabia
 - 10.6.8.2. United Arab Emirates
 - 10.6.8.3. Qatar
 - 10.6.8.4. Kuwait
 - 10.6.8.5. Oman
 - 10.6.8.6. Bahrain
 - 10.6.8.7. South Africa
 - 10.6.8.8. Egypt
 - 10.6.8.9. Nigeria
 - 10.6.8.10. Morocco
 - 10.6.8.11. Rest of Middle East & Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 11.4. Partner Identification Analysis
- 11.5. Investment & Funding Landscape
- 11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

- 12.1. Madrigal Pharmaceuticals, Inc.*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio

- 12.1.3. Revenue Analysis
- 12.1.4. Pricing Analysis
- 12.1.5. SWOT Analysis
- 12.1.6. Recent Developments
 - 12.1.6.1. Major Deals
 - 12.1.6.2. M&A
 - 12.1.6.3. Collaboration
 - 12.1.6.4. Acquisition
 - 12.1.6.5. Joint Ventures
 - 12.1.6.6. Innovations
- 12.1.7. Recent News
 - 12.1.7.1. Events
 - 12.1.7.2. Conferences
 - 12.1.7.3. Symposiums
 - 12.1.7.4. Webinars
- 12.2. Novo Nordisk A/S
- 12.3. Boehringer Ingelheim International GmbH
- 12.4. Akero Therapeutics, Inc.
- 12.5. 89bio, Inc.
- 12.6. Inventiva
- 12.7. Sagimet Biosciences Inc.
- 12.8. Viking Therapeutics
- 12.9. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
- 12.10. Gilead Sciences, Inc. . (LIST NOT EXHAUSTIVE)

13. GLOBAL METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) DRUGS MARKET – RESEARCH METHODOLOGY

- 13.1. Research Data
 - 13.1.1. Secondary Data
 - 13.1.2. Primary Data
 - 13.1.3. CAGR Analysis
- 13.2. Market Size Estimation Methodology
 - 13.2.1. Bottom-Up Approach
 - 13.2.2. Top-Down Approach
- 13.3. Market Breakdown & Data Triangulation
- 13.4. Research Assumptions
- 13.5. Limitations

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market - 2025-2033

Product link: <https://marketpublishers.com/r/GB93C7AE8C4AEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB93C7AE8C4AEN.html>